Royalty Pharma plc (RPRX) News
Follow Royalty Pharma plc (RPRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Royalty Pharma Q3 Results Expected November 4
Royalty Pharma is scheduled to report Q3'26 results before the market opens on November 4.
EQUITY | Nov 03, 2026, 12:01 PM UTC
M
RPRX Q3'26 Earnings Preview
RPRX is scheduled to report Q3'26 results on November 4 before the market opens. Revenue and EPS estimates are available.
EQUITY | Oct 28, 2026, 11:00 AM UTC
M
Royalty Pharma to report third-quarter 2026 results on Nov. 4, 2026
Royalty Pharma (RPRX) said it will announce third-quarter 2026 financial results on November 4, 2026.
EQUITY | Oct 09, 2026, 12:50 PM UTC
L
RPRX - Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
RPRX - Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEWS | Sep 15, 2026, 08:35 PM UTC
L
RPRX: Early target achievement and global expansion fuel strong growth and innovation in royalty funding
Surpassing its five-year capital deployment target early, the firm is leveraging new opportunities in Big Pharma and China, driving robust growth and innovation in R&D co-funding and synthetic royalties. Enhanced by a pr
GEOPOLITICS | Sep 14, 2026, 08:28 PM UTC
L
RPRX: Accelerated growth via innovative deals, AI-driven insights, and expanding global partnerships
Achieved capital deployment targets ahead of schedule, driven by robust deal flow and new opportunities in big pharma and China. Innovative R&D co-funding and synthetic royalty structures are fueling growth, while AI-pow
GEOPOLITICS | Sep 14, 2026, 07:34 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
L
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc NASDAQ:RPRX today announced that it will participate in the following upcoming investor conferences during the month of September:The webcast will be access
EQUITY | Sep 09, 2026, 08:11 PM UTC
L
Royalty Pharma maintained as Buy by TD Cowen
TD Cowen maintained its Buy rating on Royalty Pharma.
EQUITY | Sep 08, 2026, 02:23 PM UTC
L
RPRX - Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
RPRX - Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
EQUITY | Sep 04, 2026, 11:05 PM UTC
L
Stephens watchlist flags potential S&P Dow Jones September index changes
Stephens identified companies that could be added to, moved between, or removed from S&P Dow Jones Indices in the third-quarter rebalance after the close on Friday, September 18.
EQUITY | Sep 03, 2026, 04:05 PM UTC
M
RPRX: Royalty Pharma and Zealand Pharma Enter Funding Agreement
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
MNA | Aug 12, 2026, 08:10 PM UTC
L
RPRX - Royalty Pharma reports second quarter 2026 results
RPRX - Royalty Pharma reports second quarter 2026 results
EARNINGS | Aug 05, 2026, 11:01 AM UTC
L
RPRX Appoints Greg Raskin as SVP
RPRX appoints new Senior Vice President
EQUITY | Aug 03, 2026, 12:15 PM UTC
L
RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in
RPRX neurimmune sells a portion of its Royalty interest in cliramitug to Royalty Pharma Neurimmune: sold portion of its Royalty interest in cliramitug to Royalty Pharma for up to $425M - In Q1 of 2027, Royalty Pharma wil
EQUITY | Jul 22, 2026, 10:51 AM UTC